Nanoliposomal irinotecan in advanced biliary tract cancers
- PMID: 38870978
- DOI: 10.1016/S2468-1253(24)00151-1
Nanoliposomal irinotecan in advanced biliary tract cancers
Conflict of interest statement
DM declares honoraria for consulting or advisory roles and lectures from AbbVie, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Foundation Medicine, Incyte, LEO Pharma, Medscape, Merck Serono, MSD, Pierre Fabre, Roche, Servier, Sanofi, Taiho, and Viatris, and travel accommodations or expenses from Sanofi, Amgen, Bristol Myers Squibb, Bayer, Merck Serono, MSD, Pierre Fabre, Roche, Servier, and Viatris. RC declares no competing interests.
Comment on
-
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.Lancet Gastroenterol Hepatol. 2024 Aug;9(8):734-744. doi: 10.1016/S2468-1253(24)00119-5. Epub 2024 Jun 10. Lancet Gastroenterol Hepatol. 2024. PMID: 38870977 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
